Clinical Trials Logo

Biliary Tract Neoplasms clinical trials

View clinical trials related to Biliary Tract Neoplasms.

Filter by:

NCT ID: NCT01375972 Completed - Clinical trials for Metastatic Biliary Cancer

Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma

Start date: March 2008
Phase: Phase 2
Study type: Interventional

To select a better agent between S-1 or gemcitabine in combination with cisplatin for the conventional chemotherapy platform for future development in advanced Biliary Tract Adenocarcinoma (BTA), the investigators conduct a randomized phase II trial of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first line therapy in advanced BTA.

NCT ID: NCT01315522 Completed - Clinical trials for Biliary Tract Neoplasms

Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents

Start date: June 2010
Phase: Phase 4
Study type: Interventional

Endoscopic retrograde biliary drainage (ERBD) is now widely accepted as the standard intervention for the relief of obstructive jaundice in patients with unresectable malignant biliary obstruction. Although plastic stents (PSs) were developed earlier, self-expandable metal stents (SEMSs) are now used widely as the initial choice for ERBD in this setting, as SEMSs offer longer patency.However, SEMSs do become occluded in some patients. There are a limited number of reports on the management of occluded SEMS with various results. The aim of this study is to compare the efficacy of ComVi stents SEMSs with uncovered SEMS in subsequent ERBD after the occlusion of initial SEMSs.

NCT ID: NCT01313377 Completed - Liver Cancer Clinical Trials

Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery

Start date: July 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Observation is watching a patient's condition but not giving treatment until symptoms appear. It is not yet known whether giving gemcitabine hydrochloride together with oxaliplatin is more effective than observation in treating patients with biliary tract cancer that has been removed by surgery. PURPOSE: This randomized phase III trial is studying giving gemcitabine hydrochloride together with oxaliplatin to see how well it works compared with observation in treating patients with biliary tract cancer that has been removed by surgery.

NCT ID: NCT01308840 Completed - Clinical trials for Biliary Tract Cancer

Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

UGIH09067
Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overall survival in this population.

NCT ID: NCT01297998 Completed - Clinical trials for Biliary Tract Cancer

A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

Start date: January 2011
Phase: Phase 1
Study type: Interventional

To decide maximum tolerated dose and recommended dose of treatment using gemcitabine plus cisplatin combination therapy in patients with biliary tract cancer undergoing resection without major hepatectomy.

NCT ID: NCT01294085 Completed - Clinical trials for Biliary Tract Cancer

Case Series Study of Biliary Tract Cancer Patients in Japan

Start date: November 2010
Phase: N/A
Study type: Observational

To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.

NCT ID: NCT01291615 Completed - Clinical trials for Biliary Tract Cancer

Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Start date: December 2010
Phase: Phase 1
Study type: Interventional

To decide maximum tolerated dose and/or recommended dose of Gemcitabine or S-1 adjuvant therapy after hemihepatectomy

NCT ID: NCT01284413 Completed - Clinical trials for Biliary Tract Cancer

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety of GCS therapy for phase I and efficacy of GCS therapy for phase II.

NCT ID: NCT01242605 Completed - Cholangiocarcinoma Clinical Trials

ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer

ABC-04
Start date: February 2012
Phase: Phase 1
Study type: Interventional

The objective of this study is to establish the recommended dose of selumetinib, a novel MEK inhibitor for use in combination with gemcitabine and cisplatin.

NCT ID: NCT01127555 Completed - Clinical trials for Unresectable Biliary Tract Cancer

Salvage mFOLFOX in BTC After Failure of Gemcitabine

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.